StreetAlpha.app
Home › Stocks › ALMS

Alumis Inc. (ALMS)

Healthcare
$4.84
▼ −5.84%
LAST CLOSE · NOV 17

Alumis is a South San Francisco drug developer working on TYK2 inhibitor treatments for immune-mediated diseases. It last closed at $4.84 on Nov 17, down 5.84% on the day. The average 12-month price target from 4 analysts is $21.00 (+333.9% from the last close), with a high of $29.00 and a low of $9.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in ALMS, 100% of them bullish and 0% bearish. In the past 30 days there were 4 dark pool prints totaling $997K, the largest $315K.

AI Auto Pilots
Is ALMS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$7.2M
Net income
−$423.1M
−5844.5% margin
EPS (diluted)
−$3.53
Free cash flow
−$320.9M
−4433.3% margin
Balance sheet
Cash & equivalents
$57.7M
At Sep 30
Shareholder equity
$378.4M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$155.0M−$155.0MFY2023FY2024: −$294.2M−$294.2MFY2024FY2025: −$243.3M−$243.3MFY2025

From ALMS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on ALMS in the past 90 days
Average 12-month target
$21.00
▲ 333.9% upside

Based on 4 analysts who set a price target on ALMS in the past 90 days. The average target is $21.00, with a high of $29.00 and a low of $9.00, compared with the last close of $4.84.

Low $9.00Avg $21.00High $29.00
Blue marker: last close $4.84
Highest target$29.00
Average target$21.00
Lowest target$9.00
Latest rating changes
OppenheimerTarget lowered
Nov 16Buy$37 → $28
Wells FargoTarget lowered
Nov 13Buy$25 → $18
HC Wainwright & Co.Target lowered
Nov 13Buy$15 → $9
OppenheimerMaintained
Sep 2Buy$37
Wells FargoMaintained
Sep 2Buy$25
DateFirmActionRatingPrice target
Nov 16OppenheimerTarget loweredBuy$37 → $28
Nov 13Wells FargoTarget loweredBuy$25 → $18
Nov 13HC Wainwright & Co.Target loweredBuy$15 → $9
Sep 2OppenheimerMaintainedBuy$37
Sep 2Wells FargoMaintainedBuy$25
Loading…

Technical Analysis

ALMS · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 31% below its 20 day and 45% below its 50 day average. It is 318% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $4.70, and the nearest resistance the Pivot at $4.89.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 10.8%/day
Key levels
$31.3552 week high+547.7%
$20.24200 day average+318.2%
$16.01100 day average+230.8%
$7.0150 day average+44.8%
$6.72Swing high (Nov 11)+38.8%
$6.3520 day average+31.2%
$5.08Pivot R1+5.0%
$4.89Pivot+1.0%
$4.84Last close
$4.7052 week low−2.9%
$4.65Pivot S1−3.9%
Indicators
RSI (14)28.66Oversold below 30Oversold
MACD-0.67Below its signal lineBearish
Stochastic5.4Near the bottom of its rangeOversold
ADX (14)41.4Strong downtrend
Williams %R-94.5Oversold below −80, overbought above −20Oversold
CCI (20)-250.8Oversold below −100, overbought above 100Oversold
Rate of change−25.5%Change over 10 sessionsBearish
ATR (14)$0.52Typical daily range, 10.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALMS

What happened before

See how ALMS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Aug 21 – Aug 21
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$997K
Largest print
$315K
Loading…

ALMS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲125 buying vs 92 selling
  • ▼Shares held by funds -5.0%
  • ▲Funds holding +2
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding200198+1.0%
In funds' top 10818−55.6%
Held by funds–––
New / increased45 / 8027 / 74+23.8%
Reduced / sold out50 / 4261 / 24+8.2%
Put/call ratio0.050.02+233.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALMS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALMS is in one of them and how their past ALMS trades turned out.

ALMS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALMS in an article yet. Here's the latest on the wider market.

About Alumis

Alumis is a drug developer based in South San Francisco, California, that is working on treatments for immune-mediated diseases. Its lead candidate, envudeucitinib, is in Phase 3 testing for plaque psoriasis and is also being studied in lupus. The company is developing a second TYK2 inhibitor for neuroinflammatory conditions and holds an antibody being evaluated for thyroid eye disease. Its target patients are people living with immune-mediated diseases such as psoriasis and lupus.

Headquarters
South San Francisco, CA